risedronic acid has been researched along with Bone Fractures in 125 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures." | 9.30 | Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 8.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 7.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "This study aimed to compare direct health care costs related to the treatment of osteoporosis and osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate." | 7.75 | Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. ( Blouin, J; Dragomir, A; Fernandes, JC; Fredette, M; Perreault, S; Ste-Marie, LG, 2009) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 5.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| "Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures." | 5.30 | Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019) |
| "PURPOSE To investigate the management of bone health in women with early breast cancer (EBC) who were scheduled to receive anastrozole." | 5.14 | Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. ( Apffelstaedt, JP; Barlow, D; Campone, M; Clack, G; Eastell, R; Hannon, RA; Mackey, JR; Makris, A; Van Poznak, C, 2010) |
| " The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates." | 4.79 | Bisphosphonate therapy. ( Licata, AA, 1997) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 4.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 3.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "This study aimed to compare direct health care costs related to the treatment of osteoporosis and osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate." | 3.75 | Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. ( Blouin, J; Dragomir, A; Fernandes, JC; Fredette, M; Perreault, S; Ste-Marie, LG, 2009) |
| " Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms." | 2.82 | Novel formulations of oral bisphosphonates in the treatment of osteoporosis. ( Al-Daghri, N; Bock, O; Branco, J; Bruyère, O; Casado, E; Cavalier, E; Cooper, C; Cortet, B; de Wit, M; Fuggle, N; Giusti, A; Halbout, P; Harvey, NC; Hiligsmann, M; Kanis, JA; Kaufman, JM; Kurth, A; Maggi, S; Matijevic, R; Minisola, S; Palacios, S; Radermecker, RP; Reginster, JY; Rizzoli, R; Thomasius, F; Tuzun, S; Veronese, N, 2022) |
| "Moderate to severe osteogenesis imperfecta is associated with multiple fractures in childhood." | 2.75 | A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. ( Ahmed, F; Bishop, N; Campbell, M; Chapman, S; Eastell, R; Hall, C; Harrison, R; Hill, C; Knowles, E; Rigby, A; Shaw, N; Sprigg, A, 2010) |
| "Osteoporosis is a common condition in men that can have serious clinical consequences." | 2.74 | Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. ( Dorst, A; Faber, H; Farahmand, P; Ringe, JD, 2009) |
| "Osteoporosis is prevalent in men with an estimated one in eight men older than 50 years suffering from osteoporotic fracture, and a higher mortality rate after fracture among men compared with women." | 2.72 | Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. ( Dorst, A; Faber, H; Farahmand, P; Ringe, JD, 2006) |
| "There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in such patients." | 2.72 | Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. ( Ando, K; Higashi, M; Kanaji, A; Namisato, M; Nishio, M; Yamada, H, 2006) |
| " To assess the anti-fracture efficacy of this new regimen, we have analyzed the fracture data collected in an active controlled study of risedronate dosing regimens (the Once-a-Week study) using matched historical control data from previous placebo-controlled trials." | 2.71 | Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. ( Brown, J; Kasibhatla, C; Li, Z; Lindsay, R; Watts, NB, 2003) |
| "Greater decreases in bone resorption markers were associated with greater decreases in vertebral (and nonvertebral) fractures." | 2.71 | Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. ( Barton, I; Chines, A; Delmas, PD; Eastell, R; Garnero, P; Hannon, RA, 2003) |
| "The preferred treatment for osteoporosis in men is debated, and pairwise meta-analysis cannot obtain hierarchies of these treatments." | 2.52 | Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis. ( Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "Postmenopausal osteoporosis is a chronic disease requiring treatment that balances long-term fracture efficacy against risk." | 2.48 | Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). ( Cooper, C; Cortet, B; Diaz-Curiel, M; Kanis, JA; Lorenc, RS; Reginster, JY; Rizzoli, R, 2012) |
| "Male osteoporosis is an important public health issue and remains undertreated." | 2.45 | Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. ( Chen, JT; Zhong, ZM, 2009) |
| " The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed." | 2.45 | Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. ( Rackoff, P, 2009) |
| "Risedronate decreases strongly bone resorption and turnover via a potent inhibitory action on osteoclasts." | 2.45 | [Risedronate for treatment of osteoporosis]. ( Hagino, H, 2009) |
| "Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue resulting in compromised bone strength and an increased risk of fracture." | 2.44 | Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. ( Hochberg, MC, 2008) |
| "5 mg risedronate, and was well tolerated with favorable safety profiles compared with once-daily dosage regimen." | 2.44 | [Efficacy and tolerability of risedronate for the treatment of osteoporosis]. ( Kishimoto, H, 2008) |
| " In placebo controlled trials it has been shown to be safe and effective in preventing fractures." | 2.44 | Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. ( Adachi, JD; Bobba, R, 2007) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.43 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2005) |
| "Clinically, osteoporosis is diagnosed using dual energy x-ray absorptiometry." | 2.43 | Microcracks in cortical bone: how do they affect bone biology? ( Brennan, O; Kennedy, OD; Lee, TC; O'Brien, FJ, 2005) |
| " Nevertheless, the need to follow inconvenient dosing instructions every week could still hinder long-term compliance and therapeutic outcome." | 2.43 | Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. ( Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM, 2006) |
| " RCTs have demonstrated that the incidence of gastrointestinal tract adverse events in postmenopausal osteoporotic women treated with bisphosphonates and placebo are similar, and also the long-term efficacy and safety of alendronate and risedronate." | 2.43 | Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T, 2006) |
| "Osteoporosis is associated with increased risk of fractures at most skeletal sites." | 2.42 | [Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint]. ( Sohen, S, 2003) |
| "Alendronate has been approved for treatment of osteoporosis in men, and other treatments for men are under evaluation." | 2.41 | Osteoporosis in elderly: prevention and treatment. ( Deal, C; Srivastava, M, 2002) |
| "Key search terms were risedronate, postmenopausal osteoporosis, and fractures." | 2.41 | Risedronate for the prevention of fractures in postmenopausal osteoporosis. ( Nip, CS; Sickels, JM, 2002) |
| "Osteoporosis is a major health threat nowadays." | 1.43 | Use of drugs against osteoporosis in the Baltic countries during 2010-2014. ( Kõks, S; Laius, O; Maasalu, K; Märtson, A, 2016) |
| " Although existing evidence supports a good safety profile, there is concern that chronic administration of these agents could result in severe suppression of bone turnover with increased risk of nonvertebral fractures." | 1.36 | Unusual mid-shaft fractures during long-term bisphosphonate therapy. ( Levy, S; Odvina, CV; Rao, DS; Rao, S; Zerwekh, JE, 2010) |
| "We studied 1515 women with postmenopausal osteoporosis under treatment with anti-resorbing agents (alendronate, risedronate, raloxifene) for 13." | 1.35 | Vitamin D status and response to treatment in post-menopausal osteoporosis. ( Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L, 2009) |
| "Osteoporosis is widely prevalent in India and osteoporotic fractures are a common cause of morbidity and mortality." | 1.35 | Osteoporotic fracture management in India: a survey of orthopaedic surgeons. ( Lakhotia, SM, 2008) |
| "Postmenopausal women with osteopenia, defined as femoral neck T-score between -1 and -2." | 1.35 | Effects of risedronate on fracture risk in postmenopausal women with osteopenia. ( Barton, IP; Grauer, A; McClung, MR; Simon, JA; Siris, ES, 2008) |
| "A total of 69 men with prostate cancer were assigned to receive either oral risedronate or none during ADT (hormone naïve)." | 1.35 | [Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy]. ( Bab, S; Hayakawa, K; Hyodo, T; Iwamura, M; Kimura, M; Matsumoto, K; Okazaki, M; Satoh, T; Soh, S; Tabata, K; Tsuboi, T; Yokoyama, E, 2008) |
| "Alendronate was the reference category in all analyses." | 1.35 | Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. ( Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T, 2008) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 1.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.60) | 18.2507 |
| 2000's | 87 (69.60) | 29.6817 |
| 2010's | 32 (25.60) | 24.3611 |
| 2020's | 4 (3.20) | 2.80 |
| Authors | Studies |
|---|---|
| McConnell, M | 1 |
| Shieh, A | 1 |
| Fuggle, N | 1 |
| Al-Daghri, N | 1 |
| Bock, O | 1 |
| Branco, J | 1 |
| Bruyère, O | 1 |
| Casado, E | 2 |
| Cavalier, E | 1 |
| Cortet, B | 3 |
| de Wit, M | 1 |
| Giusti, A | 1 |
| Halbout, P | 1 |
| Harvey, NC | 1 |
| Hiligsmann, M | 1 |
| Kaufman, JM | 1 |
| Kurth, A | 1 |
| Maggi, S | 2 |
| Matijevic, R | 1 |
| Minisola, S | 4 |
| Palacios, S | 1 |
| Radermecker, RP | 1 |
| Thomasius, F | 2 |
| Tuzun, S | 1 |
| Veronese, N | 1 |
| Kanis, JA | 2 |
| Reginster, JY | 3 |
| Rizzoli, R | 3 |
| Cooper, C | 2 |
| Eisman, JA | 1 |
| Boolell, M | 2 |
| Ionescu-Ittu, R | 1 |
| Vekeman, F | 1 |
| Heroux, J | 1 |
| Rosas, J | 1 |
| Rubio-Terrés, C | 1 |
| Rubio-Rodríguez, D | 1 |
| Arístegui, I | 1 |
| Karlsson, L | 1 |
| Mesterton, J | 1 |
| Tepie, MF | 1 |
| Intorcia, M | 1 |
| Overbeek, J | 1 |
| Ström, O | 1 |
| Sestak, I | 1 |
| Blake, GM | 1 |
| Patel, R | 1 |
| Coleman, RE | 1 |
| Cuzick, J | 1 |
| Eastell, R | 7 |
| Nakamura, T | 2 |
| Nakano, T | 1 |
| Ito, M | 2 |
| Hagino, H | 3 |
| Hashimoto, J | 2 |
| Tobinai, M | 2 |
| Mizunuma, H | 1 |
| Sato, Y | 2 |
| Honda, Y | 1 |
| Iwamoto, J | 5 |
| Amano, N | 1 |
| Yano, T | 1 |
| Yamada, M | 1 |
| Konda, T | 1 |
| Shiozaki, M | 1 |
| Inoue, D | 1 |
| Soen, S | 1 |
| Yoshida, S | 1 |
| Matsunaga, M | 1 |
| Mellibovsky, L | 1 |
| Prieto-Alhambra, D | 1 |
| Mellibovsky, F | 1 |
| Güerri-Fernández, R | 1 |
| Nogués, X | 1 |
| Randall, C | 1 |
| Hansma, PK | 1 |
| Díez-Perez, A | 1 |
| Takakuwa, M | 3 |
| Chen, LX | 1 |
| Zhou, ZR | 1 |
| Li, YL | 1 |
| Ning, GZ | 1 |
| Zhang, TS | 1 |
| Zhang, D | 1 |
| Feng, SQ | 1 |
| Gatti, D | 1 |
| Adami, S | 5 |
| Viapiana, O | 1 |
| Rossini, M | 2 |
| Veszelyné Kotán, E | 1 |
| Mészaros, Á | 1 |
| Laius, O | 1 |
| Maasalu, K | 1 |
| Kõks, S | 1 |
| Märtson, A | 1 |
| Inderjeeth, CA | 2 |
| Inderjeeth, AJ | 1 |
| Raymond, WD | 1 |
| Giannini, S | 1 |
| Bianchi, G | 1 |
| Sinigaglia, L | 3 |
| Di Munno, O | 1 |
| Fiore, CE | 1 |
| Hochberg, MC | 2 |
| Ringe, JD | 4 |
| Farahmand, P | 2 |
| Faber, H | 2 |
| Dorst, A | 2 |
| Tosteson, AN | 1 |
| Burge, RT | 1 |
| Marshall, DA | 1 |
| Lindsay, R | 4 |
| Kishimoto, H | 1 |
| Bonnick, SL | 1 |
| Beck, TJ | 1 |
| Cosman, F | 1 |
| Wang, H | 1 |
| de Papp, AE | 2 |
| Lakhotia, SM | 1 |
| Verhaar, HJ | 1 |
| Sheehy, O | 1 |
| Kindundu, CM | 1 |
| Barbeau, M | 1 |
| LeLorier, J | 1 |
| Blouin, J | 2 |
| Dragomir, A | 2 |
| Fredette, M | 1 |
| Ste-Marie, LG | 3 |
| Fernandes, JC | 2 |
| Perreault, S | 2 |
| Foo, AC | 1 |
| Lai, MM | 1 |
| Glendenning, P | 1 |
| Majima, T | 1 |
| Shimatsu, A | 1 |
| Komatsu, Y | 1 |
| Satoh, N | 1 |
| Fukao, A | 1 |
| Ninomiya, K | 1 |
| Matsumura, T | 1 |
| Nakao, K | 1 |
| Geusens, P | 4 |
| Rauch, F | 1 |
| Munns, CF | 1 |
| Land, C | 1 |
| Cheung, M | 1 |
| Glorieux, FH | 1 |
| Wang, X | 1 |
| Erickson, AM | 1 |
| Allen, MR | 1 |
| Burr, DB | 2 |
| Martin, RB | 1 |
| Hazelwood, SJ | 1 |
| Odvina, CV | 1 |
| Levy, S | 1 |
| Rao, S | 1 |
| Zerwekh, JE | 1 |
| Rao, DS | 1 |
| Chapurlat, RD | 1 |
| Zhong, ZM | 1 |
| Chen, JT | 1 |
| Rackoff, P | 1 |
| Bishop, N | 1 |
| Harrison, R | 1 |
| Ahmed, F | 1 |
| Shaw, N | 1 |
| Campbell, M | 1 |
| Knowles, E | 1 |
| Hill, C | 1 |
| Hall, C | 1 |
| Chapman, S | 1 |
| Sprigg, A | 1 |
| Rigby, A | 1 |
| Van Poznak, C | 1 |
| Hannon, RA | 4 |
| Mackey, JR | 1 |
| Campone, M | 1 |
| Apffelstaedt, JP | 1 |
| Clack, G | 1 |
| Barlow, D | 1 |
| Makris, A | 1 |
| Bolland, MJ | 1 |
| Grey, AB | 1 |
| Gamble, GD | 1 |
| Reid, IR | 1 |
| Berto, P | 1 |
| Noale, M | 1 |
| Lopatriello, S | 1 |
| Shiraki, M | 1 |
| Yamazaki, Y | 1 |
| Shiraki, Y | 1 |
| Hosoi, T | 1 |
| Tsugawa, N | 1 |
| Okano, T | 1 |
| Boonen, S | 4 |
| Klemes, AB | 1 |
| Zhou, X | 1 |
| Konishi, M | 1 |
| Zhou, Q | 1 |
| Itabashi, K | 2 |
| Alvarez, A | 1 |
| Kremer, R | 1 |
| Weiss, DR | 1 |
| Benedetti, A | 1 |
| Haziza, M | 1 |
| Trojan, DA | 1 |
| Winzenberg, T | 1 |
| Jones, G | 1 |
| Vrijens, B | 1 |
| Cahall, DL | 1 |
| Garnero, P | 3 |
| Watts, NB | 7 |
| Geoffroy, V | 1 |
| Paschalis, EP | 2 |
| Libouban, H | 1 |
| Blouin, S | 1 |
| Ostertag, A | 1 |
| Chappard, D | 1 |
| Cros, M | 1 |
| Phipps, R | 2 |
| de Vernejoul, MC | 1 |
| Bradbury, LA | 1 |
| Barlow, S | 1 |
| Geoghegan, F | 1 |
| Stuckey, SL | 1 |
| Wass, JA | 1 |
| Russell, RG | 1 |
| Brown, MA | 1 |
| Duncan, EL | 1 |
| Ott, SM | 1 |
| Martin, KE | 1 |
| Yu, J | 1 |
| Campbell, HE | 1 |
| Abarca, J | 1 |
| White, TJ | 1 |
| Diaz-Curiel, M | 2 |
| Lorenc, RS | 1 |
| Davey, DA | 1 |
| Välimäki, MJ | 1 |
| Cranney, A | 3 |
| Tugwell, P | 3 |
| Adachi, J | 1 |
| Weaver, B | 2 |
| Zytaruk, N | 2 |
| Papaioannou, A | 2 |
| Robinson, V | 3 |
| Shea, B | 3 |
| Wells, G | 3 |
| Guyatt, G | 2 |
| Collier, J | 1 |
| Srivastava, M | 1 |
| Deal, C | 1 |
| Baranauskaite, A | 1 |
| Savickiene, A | 1 |
| Sohen, S | 1 |
| Li, Z | 1 |
| Kasibhatla, C | 2 |
| Brown, J | 2 |
| Barton, I | 2 |
| Chines, A | 1 |
| Delmas, PD | 4 |
| Ettinger, MP | 2 |
| Waldegger, L | 1 |
| Adachi, JD | 2 |
| Harrington, JT | 1 |
| Brandi, ML | 1 |
| Civitelli, R | 1 |
| Fardellone, P | 1 |
| Grauer, A | 2 |
| Marx, J | 1 |
| Vanderschueren, D | 1 |
| Zizic, TM | 2 |
| Lange, U | 1 |
| Illgner, U | 1 |
| Teichmann, J | 1 |
| Schleenbecker, H | 1 |
| Pande, I | 1 |
| Hosking, DJ | 1 |
| Stevenson, M | 2 |
| Jones, ML | 1 |
| De Nigris, E | 1 |
| Brewer, N | 1 |
| Davis, S | 1 |
| Oakley, J | 1 |
| Laan, RF | 1 |
| Barton, IP | 3 |
| Maricic, M | 1 |
| O'Brien, FJ | 1 |
| Brennan, O | 1 |
| Kennedy, OD | 1 |
| Lee, TC | 1 |
| Felsenberg, D | 1 |
| Takada, J | 1 |
| Thomas, T | 1 |
| Reach, G | 1 |
| Lespessailles, E | 1 |
| Epstein, S | 1 |
| Emkey, R | 1 |
| Wilson, KM | 1 |
| Hiltbrunner, V | 1 |
| Schimmer, RC | 1 |
| Gass, M | 1 |
| Dawson-Hughes, B | 1 |
| Bonnick, S | 1 |
| Saag, KG | 1 |
| Kiel, DP | 1 |
| McClung, M | 3 |
| Hochberg, M | 1 |
| Burnett, SM | 1 |
| Sebba, A | 1 |
| Kagan, R | 1 |
| Chen, E | 1 |
| Thompson, DE | 1 |
| Troen, BR | 1 |
| Takeda, T | 1 |
| Zoehrer, R | 1 |
| Roschger, P | 1 |
| Hofstaetter, JG | 1 |
| Durchschlag, E | 1 |
| Fratzl, P | 1 |
| Klaushofer, K | 1 |
| Kanaji, A | 1 |
| Higashi, M | 1 |
| Namisato, M | 1 |
| Nishio, M | 1 |
| Ando, K | 1 |
| Yamada, H | 1 |
| Isaia, G | 3 |
| Luisetto, G | 2 |
| Gentilella, R | 2 |
| Agnusdei, D | 2 |
| Iori, N | 1 |
| Nuti, R | 2 |
| Silverman, SL | 1 |
| Lange, JL | 1 |
| Moro Alvarez, MJ | 1 |
| Karam, R | 1 |
| Camm, J | 1 |
| Campbell, MJ | 1 |
| Siris, ES | 1 |
| Simon, JA | 1 |
| McClung, MR | 2 |
| Bobba, R | 1 |
| Cesareo, R | 1 |
| Iozzino, M | 1 |
| Alva, D | 1 |
| Napolitano, C | 1 |
| De Rosa, B | 1 |
| Contini, S | 1 |
| Mallardo, L | 1 |
| Lauria, A | 1 |
| Reda, G | 1 |
| Orsini, A | 1 |
| Ding, H | 1 |
| Koinuma, N | 1 |
| Monma, Y | 1 |
| Tanaka, I | 1 |
| Oshima, H | 1 |
| Peterson, J | 1 |
| Boucher, M | 1 |
| Coyle, D | 1 |
| Kimura, M | 1 |
| Satoh, T | 1 |
| Okazaki, M | 1 |
| Tabata, K | 1 |
| Tsuboi, T | 1 |
| Hyodo, T | 1 |
| Yokoyama, E | 1 |
| Matsumoto, K | 1 |
| Soh, S | 1 |
| Iwamura, M | 1 |
| Hayakawa, K | 1 |
| Bab, S | 1 |
| Katayama, K | 1 |
| Matsuno, T | 1 |
| Silvestri, S | 1 |
| Anić, B | 1 |
| Cadarette, SM | 1 |
| Katz, JN | 1 |
| Brookhart, MA | 1 |
| Stürmer, T | 1 |
| Stedman, MR | 1 |
| Solomon, DH | 1 |
| Moride, Y | 1 |
| Licata, AA | 1 |
| Harris, ST | 2 |
| Genant, HK | 1 |
| McKeever, CD | 1 |
| Hangartner, T | 1 |
| Keller, M | 1 |
| Chesnut, CH | 2 |
| Eriksen, EF | 2 |
| Hoseyni, MS | 1 |
| Axelrod, DW | 1 |
| Miller, PD | 2 |
| Lems, WF | 1 |
| Dijkmans, BA | 1 |
| Baran, DT | 1 |
| Zippel, H | 1 |
| Bensen, WG | 1 |
| Roux, C | 1 |
| Fogelman, I | 2 |
| Diamond, T | 1 |
| Meunier, PJ | 1 |
| Recker, RR | 1 |
| Heaney, RP | 2 |
| Davidson, M | 1 |
| Moffett, AH | 1 |
| Baylink, DJ | 1 |
| Crusan, CE | 1 |
| Chines, AA | 1 |
| McCormack, J | 1 |
| McClung, B | 1 |
| Li, J | 1 |
| Mashiba, T | 1 |
| Sickels, JM | 1 |
| Nip, CS | 1 |
| Hodsman, AB | 1 |
| Hanley, DA | 1 |
| Josse, R | 1 |
| Roll, KT | 1 |
| Olszynski, WP | 1 |
| Alsayed, N | 1 |
| Davie, MW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Resolution of Hyperparathyroidism With High-dose Vitamin D Improves Osteoporosis in Multi-treated Postmenopausal Women[NCT05347082] | 47 participants (Actual) | Interventional | 2021-04-29 | Completed | |||
| A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis[NCT00092014] | Phase 3 | 1,053 participants (Actual) | Interventional | 2002-09-01 | Completed | ||
| Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203] | Phase 2 | 120 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
49 reviews available for risedronic acid and Bone Fractures
| Article | Year |
|---|---|
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Hum | 2022 |
Novel formulations of oral bisphosphonates in the treatment of osteoporosis.
Topics: Alendronate; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid | 2022 |
[Glucocorticoid and bone].
Topics: Administration, Ophthalmic; Adult; Aged; Alendronate; Animals; Bone Density; Bone Density Conservati | 2014 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans | 2015 |
The use of bisphosphonates in women: when to use and when to stop.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Iban | 2015 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic A | 2016 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relations | 2008 |
[Efficacy and tolerability of risedronate for the treatment of osteoporosis].
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Fractures, | 2008 |
Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Organometall | 2009 |
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Frac | 2009 |
Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Follow | 2009 |
[Risedronate for treatment of osteoporosis].
Topics: Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Fractures, Bone; Fractures, Spont | 2009 |
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Topics: Aged; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug-Related Side Effects | 2009 |
Effect of osteoporosis treatment on mortality: a meta-analysis.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2010 |
Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
Topics: Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cli | 2010 |
Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Topics: Adolescent; Adult; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling | 2012 |
What is the optimal duration of bisphosphonate therapy?
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Femoral F | 2011 |
Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; | 2012 |
Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.
Topics: Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Randomized Controlled | 2002 |
Osteoporosis in elderly: prevention and treatment.
Topics: Aged; Alendronate; Etidronic Acid; Exercise; Female; Fractures, Bone; Hormone Replacement Therapy; H | 2002 |
[Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint].
Topics: Alendronate; Etidronic Acid; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid | 2003 |
[Osteoporosis in men].
Topics: Alendronate; Androgens; Calcium Channel Blockers; Diagnosis, Differential; Etidronic Acid; Fractures | 2003 |
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Topics: Aged; Alendronate; Calcium Channel Blockers; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2003 |
Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Topics: Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Randomi | 2003 |
Fracture protection in osteoporosis with risedronate.
Topics: Aged; Bone Density; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Ag | 2004 |
Pharmacologic prevention of osteoporotic fractures.
Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; | 2004 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, C | 2005 |
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysi | 2005 |
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Middle | 2005 |
Glucocorticoid-induced osteoporosis: treatment options and guidelines.
Topics: Alendronate; Bone Density; Bone Resorption; Diphosphonates; Etidronic Acid; Exercise; Female; Fractu | 2005 |
Microcracks in cortical bone: how do they affect bone biology?
Topics: Animals; Bone and Bones; Bone Matrix; Bone Remodeling; Calcium Channel Blockers; Etidronic Acid; Fra | 2005 |
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Etidronic | 2005 |
[Application of anti-resorptive drugs for the treatment of osteoporosis].
Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; | 2006 |
[Your patients face the treatment of osteoporosis: How to improve the efficacy of management in clinical practice?].
Topics: Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Congresses as Topic; | 2006 |
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administra | 2006 |
Preventing osteoporosis-related fractures: an overview.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone D | 2006 |
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; | 2006 |
Pharmacological treatment of osteoporosis for people over 70.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractu | 2007 |
Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.
Topics: Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fractures, | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosph | 2007 |
[FACT study].
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double- | 2007 |
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Os | 2008 |
[Risedronate (Actonel)--from randomized clinical trials to real life].
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Pos | 2007 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; | 1997 |
[Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Topics: Alendronate; Bone Density; Calcitonin; Calcium Channel Blockers; Densitometry; Etidronic Acid; Femal | 2000 |
Osteoporosis: which current treatments reduce fracture risk?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Calcium Channel Blockers; Estrogen R | 2000 |
Treatment of osteoporosis with bisphosphonates.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Fem | 2001 |
Pharmacologic therapy for the treatment and prevention of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2001 |
Risedronate for the prevention of fractures in postmenopausal osteoporosis.
Topics: Aged; Clinical Trials as Topic; Etidronic Acid; Female; Fractures, Bone; Humans; MEDLINE; Osteoporos | 2002 |
24 trials available for risedronic acid and Bone Fractures
| Article | Year |
|---|---|
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.
Topics: Anastrozole; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Female; Frac | 2019 |
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; E | 2013 |
Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease.
Topics: Accidental Falls; Aged; Alzheimer Disease; Body Mass Index; Bone Density; Bone Density Conservation | 2013 |
Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractu | 2014 |
Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
Topics: Aged; Back Pain; Bone Density Conservation Agents; Calcium; Drug Therapy, Combination; Etidronic Aci | 2009 |
Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
Topics: Aged; Asian People; Back Pain; Body Height; Bone Density; Bone Density Conservation Agents; Bone Rem | 2009 |
Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Topics: Administration, Oral; Adolescent; Biomarkers; Bone Density; Bone Density Conservation Agents; Child; | 2009 |
A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Administration, Oral; Adolescent; Age Determination by Skeleton; Bone Densit | 2010 |
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2010 |
Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence.
Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Etidronic Acid; Female; Fractures, Bone; Humans; In | 2011 |
Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Topics: Adolescent; Adult; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling | 2012 |
Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.
Topics: Aged; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Humans; Middl | 2003 |
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
Topics: Aged; Biomarkers; Bone Resorption; Calcium Channel Blockers; Collagen; Collagen Type I; Etidronic Ac | 2003 |
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
Topics: Aged; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Fractures | 2004 |
Skeletal benefit after one year of risedronate therapy in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis: a prospective study.
Topics: Alkaline Phosphatase; Arthritis, Rheumatoid; Bone and Bones; C-Reactive Protein; Cross-Linking Reage | 2004 |
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
Topics: Aged; Back Pain; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Fractures, | 2006 |
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Femur | 2006 |
Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
Topics: Biopsy; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Etidronic Acid; | 2006 |
Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Bli | 2006 |
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density Con | 2008 |
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Topics: Aged; Analysis of Variance; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Fema | 1999 |
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, | 2001 |
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
Topics: Aged; Bone and Bones; Bone Density; Double-Blind Method; Drug Therapy, Combination; Estrogen Replace | 2001 |
Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Huma | 2002 |
53 other studies available for risedronic acid and Bone Fractures
| Article | Year |
|---|---|
Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bo | 2023 |
Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid | 2023 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic | 2017 |
Risedronate improves bone architecture and strength faster than alendronate in ovariectomized rats on a low-calcium diet.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Femal | 2014 |
Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; | 2015 |
Five-year experience with risedronate therapy for patients with increased fracture risk: a practice-based observational study.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agen | 2015 |
Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
Topics: Alendronate; Baltic States; Bone Density Conservation Agents; Calcium Channel Blockers; Denosumab; D | 2016 |
Medication selection and patient compliance in the clinical management of osteoporosis.
Topics: Australia; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Patient Compliance; Ph | 2016 |
Vitamin D status and response to treatment in post-menopausal osteoporosis.
Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation A | 2009 |
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Budgets; Cost-Benefit Analys | 2008 |
DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Diphosphonates; Etidronic Acid; Female; Femur; Fr | 2009 |
Osteoporotic fracture management in India: a survey of orthopaedic surgeons.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; | 2008 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Ag | 2008 |
Differences in persistence among different weekly oral bisphosphonate medications.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Confidence Intervals; Etidronic Acid; Female; F | 2009 |
Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.
Topics: Alendronate; Animals; Computer Simulation; Disease Models, Animal; Dogs; Etidronic Acid; Fractures, | 2009 |
Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Topics: Adult; Aged; Alendronate; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidroni | 2010 |
Bone microdamage.
Topics: Animals; Bone Density Conservation Agents; Bone Remodeling; Dogs; Dose-Response Relationship, Drug; | 2009 |
Corticosteroids: no drug prevention of fractures needed.
Topics: Adrenal Cortex Hormones; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents | 2009 |
Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Costs | 2010 |
High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; F | 2010 |
Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur Neck; Fractures, | 2011 |
Response of postpoliomyelitis patients to bisphosphonate treatment.
Topics: Administration, Oral; Alendronate; Bone Density; Bone Density Conservation Agents; Case-Control Stud | 2010 |
When do bisphosphonates make the most sense?
Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Re | 2011 |
Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Core Binding Factor Alph | 2011 |
Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Comparative Effectiveness Research; Diph | 2011 |
Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agen | 2012 |
Osteoporosis, osteopenia and fracture risk: widening the therapeutic horizons.
Topics: Adult; Age Factors; Aged; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Diseases, | 2012 |
[Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Topics: Alendronate; Bone Density; Calcitonin; Etidronic Acid; Fractures, Bone; Health Services Accessibilit | 2001 |
Commentary on: Bone mineral density and fracture prevalence in long-term kidney graft recipients.
Topics: Bone Density; Etidronic Acid; Fractures, Bone; Humans; Kidney Transplantation; Osteoporosis; Prevale | 2002 |
[Osteoporosis: diagnosis, prevention and treatment].
Topics: Adult; Aged; Calcitonin; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Fractures | 2002 |
[To treat effectively without delay. The data on fractures decisive].
Topics: Aged; Calcium Channel Blockers; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dipho | 2003 |
Coming to grips with bone loss.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Carrier Proteins; Estrenes; Est | 2004 |
[Calcium gaps in osteoporosis patients close. Blister pack simplifies comedication of calcium and bisphosphonates].
Topics: Alendronate; Calcitonin; Calcium; Clinical Trials as Topic; Cohort Studies; Drug Packaging; Etidroni | 2005 |
[Excellent adjustment with greater action. To pay attention to improving compliance].
Topics: Aged; Calcium; Clinical Trials as Topic; Cross-Over Studies; Diphosphonates; Drug Packaging; Drug Th | 2005 |
Osteoporosis in older people: a tale of two studies (and three treatments).
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Hum | 2006 |
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans | 2006 |
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Evaluation; Etidronic A | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diph | 2007 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2007 |
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis.
Topics: Access to Information; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; | 2007 |
Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Eti | 2008 |
The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis.
Topics: Aged; Aged, 80 and over; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Bone; Humans; Jap | 2008 |
[Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy].
Topics: Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fracture | 2008 |
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
Topics: Adult; Age Factors; Aged; Alendronate; Body Mass Index; Bone Density Conservation Agents; Etidronic | 2008 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Epidemiologic Methods; Etidr | 2008 |
The role of combination treatment for osteoporosis.
Topics: Aged; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bo | 2001 |
Absolute vs. relative numbers in evaluating drug therapy.
Topics: Alendronate; Data Interpretation, Statistical; Etidronic Acid; Female; Fractures, Bone; Humans; Info | 2001 |
Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage.
Topics: Alendronate; Animals; Bone Density; Bone Regeneration; Diphosphonates; Dogs; Etidronic Acid; Female; | 2001 |
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
Topics: Aged; Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; | 2002 |
Risedronate: a new oral bisphosphonate.
Topics: Aged; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Postmenopause; | 2002 |